StockNews.AI
ZBIO
StockNews.AI
60 days

Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

1. Zenas granted stock options for 112,000 shares to a new employee. 2. Stock options have a ten-year term and a $9.97 exercise price. 3. Options vest over four years, encouraging employee retention. 4. Zenas focuses on therapies for autoimmune diseases with obexelimab as a lead candidate. 5. Obexelimab targets B cell lineage, showing promise for chronic autoimmune conditions.

4m saved
Insight
Article

FAQ

Why Bullish?

Stock options can motivate employee performance, positively influencing future company growth.

How important is it?

The grant underscores Zenas' commitment to growth, impacting future investor confidence.

Why Long Term?

Retention incentives align with Zenas’ innovation strategy, potentially yielding results over time.

Related Companies

BMYVRTXABBVREGNAMGN
June 20, 2025 16:15 ET  | Source: Zenas BioPharma WALTHAM, Mass., June 20, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies for autoimmune diseases, today announced that on June 16, 2025 (the “Grant Date”), the Compensation Committee of the Company’s Board of Directors granted a non-qualified stock option to purchase 112,000 shares of the Company’s common stock to a newly hired employee of the Company as an inducement material to such employee’s entry into employment with the Company, in accordance with Nasdaq Listing Rule 5635(c)(4) (the “Inducement Grant”). The Inducement Grant has a ten-year term and an exercise price per share of $9.97, which is equal to the closing price of Zenas’ common stock on the Grant Date. The Inducement Grant will vest over a four-year period, with 25% of the shares vesting on the one-year anniversary of the employee’s first day of employment with the Company, and thereafter the remainder of the option will vest in 36 equal monthly installments, subject to the employee’s continued service with Zenas through the applicable vesting dates. The Inducement Grant was granted pursuant to, and is subject to, the terms and conditions of an Inducement Option Award Agreement. About Zenas BioPharma, Inc.Zenas is a clinical-stage global biopharmaceutical company committed to becoming a leader in the development and commercialization of transformative therapies for patients with autoimmune diseases. Our core business strategy combines our experienced leadership team with a disciplined product candidate acquisition approach to identify, acquire and develop product candidates globally that we believe can provide superior clinical benefits to patients living with autoimmune diseases. Zenas’ lead product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcγRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. We believe that obexelimab’s unique mechanism of action and self-administered, subcutaneous injection regimen may broadly and effectively address the pathogenic role of B cell lineage in chronic autoimmune disease. For more information about Zenas BioPharma, please visit www.zenasbio.com and follow us on LinkedIn. The Zenas BioPharma word mark, logo mark, and the “lightning bolt” design are trademarks of Zenas BioPharma, Inc. or its affiliated companies. All rights reserved. Investor and Media Contact:Argot PartnersZenas@argotpartners.com

Related News